HIV Infections
Conditions
Keywords
SCH-D, Schering D, Treatment Experienced, Entry Inhibitors, Fusion Inhibitors, Vicriviroc
Brief summary
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs. This study will test the safety and effectiveness of three different doses of vicriviroc (formerly known as Schering D, SCH-D, or SCH 417690) in HIV infected patients.
Detailed description
Vicriviroc is an oral HIV-1 entry inhibitor that targets the CCR5 receptor of T cells. Vicriviroc has been shown safe, well-tolerated, and active in Phase I clinical trials in treatment-naive HIV infected patients. The goal of this study is to evaluate the antiretroviral activity of three dose levels of vicriviroc in HIV infected, treatment-experienced patients who are failing their current ritonavir-containing antiretroviral therapy (ART). The study will last at least 48 weeks, but no more than 5 years. There are 3 steps in this study. Patients will be randomly assigned to one of 4 groups. Group 1 will receive placebo; Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment. All patients will continue their current ART (not provided by the study). After two weeks, patients will receive ART optimized by the results of genotypic/phenotypic testing performed at study screening. All participants who have received or are receiving vicriviroc will enter Step 3 and be followed for an additional 4 years. Participants who complete the study may be eligible to receive vicriviroc through a rollover study sponsored by Schering-Plough, the drug's manufacturer. Physical exams and blood collection will occur at study entry, Day 4, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48. Additionally, blood will be drawn twice, at least 2 hours apart, at both Weeks 2 and 8 for vicriviroc pharmacokinetic analysis. Patients will undergo an electrocardiogram (EKG) at Weeks 2, 8, 24, and 48. Patients will be assessed for peripheral neuropathy at study entry and Weeks 24 and 48, and will be asked to complete an adherence questionnaire at entry and Weeks 2, 8, 16, 24, 32, 40, and 48. For Step 3 participants undergoing follow-up, physical exams and blood work will occur every 6 months for 4 years. Five participants currently enrolled at four sites that are no longer receiving funding and who will not be transferred or redirected to a site within their proximity will be subject to the following changes. There will no longer be follow-up visits per the schedule of events described in the protocol. Instead, participants will have their follow-up limited to self-report through telephone interviews to ascertain vital status, occurrence of malignancies (if any), and collection of information such as HIV-1 RNA and CD4 cell count. For these participants only, the HIV-1 RNA and CD4 cell count will be done as part of the participant's clinical care and will not be paid for by the study. The follow-up telephone interviews will be conducted at six-month intervals using the script provided by the study team.
Interventions
DRUGSCH-D (vicriviroc)
Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
DRUGPlacebo
Patients in Group 1 will receive placebo.
Sponsors
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
National Institute of Allergy and Infectious Diseases (NIAID)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Note: This study was closed to screening on 09/20/05 and to enrollment on 10/20/05. Inclusion Criteria for Step 1: * HIV infected * Experiencing virologic failure on current ART regimen * Current ART regimen contains ritonavir (100 to 800 mg/day) and has been stable for at least 8 weeks prior to study entry. If amprenavir or fosamprenavir is part of the regimen, 200 to 800 mg/day ritonavir must be used for at least 2 weeks prior to study entry. * Experienced virologic failure on at least one ART regimen containing 3 or more drugs prior to current failing regimen * CD4 count of 50 cells/mm3 or more within 6 weeks prior to study entry * HIV viral load of 5,000 copies/ml or more within 6 weeks prior to study entry * HIV strain of R5-only phenotype within 6 weeks prior to study entry * Willing to use acceptable forms of contraception * Able and willing to adhere to study dose and visit schedules Inclusion Criteria for Step 2: * HIV viral load not suppressed by at least 1log10 below baseline viral load by Week 16 or after * QTc interval on EKG less than 500 msec, and less than 60 msec increase from baseline within 14 days of Step 2 entry Inclusion Criteria for Step 3: * Use of vicriviroc in Step 1 or 2 of this study or the Schering rollover study. Participants who are currently not taking vicriviroc are eligible.
Exclusion criteria
for Step 1: * Hepatitis C antibody and RNA positive * Hepatitis B surface antigen positive * Efavirenz or nevirapine use within 8 weeks of study entry * Vaccination within 2 weeks prior to study screening * Investigational agents within 30 days prior to study entry * Systemic cancer chemotherapy or other systemic cytotoxic agents within 30 days prior to study entry * Immunosuppressants within 30 days prior to study entry. Systemic corticosteroids at replacement doses (10 mg/day prednisone or less) are not excluded. * Immunomodulators within 30 days prior to study entry * Considered at risk for seizure: history of seizure, recent history of head trauma with loss of consciousness, central nervous system (CNS) tumors, or other CNS problems that, in the opinion of the investigator, pose increased risk for seizure * Medications to prevent seizures or with the potential to cause seizures within 30 days prior to study entry * Allergy to SCH 417690 or its components * Alcohol or drug abuse that, in the opinion of the investigator, would interfere with the study * Serious illness requiring systemic treatment or hospitalization. A patient who is clinically stable on therapy is not excluded. * Any clinically significant disease or condition that, in the opinion of the investigator, may interfere with the study * Require certain medications * Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in HIV-1 viral load | From baseline to Day 14 |
Secondary
| Measure | Time frame |
|---|---|
| Virologic and immunologic outcomes | Throughout the study |
| Clinical outcomes | Throughout the study |
| Safety and tolerability | Throughout the study |
| Viral coreceptor phenotype | At study entry, Day 4, and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 |
| Adherence measures | At study entry and Weeks 2, 8, 16, 24, 32, 40, and 48 |
| Pharmacokinetic outcomes | At Weeks 2 and 8 |
Countries
United States
Outcome results
None listed